Background: The benefit of catheter-directed thrombolysis for peripheral arterial occlusions is limited by hemorrhagic complications. Plasma fibrinogen level (PFL) has been suggested as a predictor of these hemorrhagic complications, but the accurateness of prediction is unknown. We summarized the available evidence on the predictive value of PFL for hemorrhagic complications after catheter-directed thrombolysis for acute or subacute peripheral native artery or arterial bypass occlusions.
Acute or subacute arterial occlusive disease of the extremities is a severe and potentially limb-threatening condition that requires urgent medical evaluation and management. 1 Both thrombolysis and surgery aim at early and full revascularization and decrease the risk of limb loss. 2, 3 These treatment modalities show no difference in limb salvage or death at 1 year. 2 Limb salvage after thrombolysis at 6 months of 72% to 93% and survival after 12 months of 80% to 94% have been reported. [4] [5] [6] [7] However, catheter-directed thrombolysis was associated with an 8.8% risk of major hemorrhage within 30 days in four trials 2 and an up to 43.8% risk for minor hemorrhage. [8] [9] [10] In search for predictors of these adverse events, absolute plasma fibrinogen level (PFL) or a relative decrease in PFL has been suggested to monitor thrombolytic therapy and to predict hemorrhagic complications, but the timing and frequency of PFL measurement during treatment vary in clinical practice. In the Surgery versus Thrombolysis for Ischemia of the Lower Extremity (STILE) trial, a significantly lower median PFL at the end of infusion was found in patients with major hemorrhage (188 mg/dL) compared with patients without hemorrhage (310 mg/dL). 4 In addition, a PFL of <100 mg/dL and a PFL of <150 mg/dL as thresholds for abortion of thrombolytic therapy have been proposed. [11] [12] [13] [14] However, data on the predictive value of PFL for hemorrhagic complications are inconsistent. [15] [16] [17] Because revascularization options may be severely hampered by preliminary abortion of thrombolytic therapy, it is of limb-saving importance to know whether to intervene or when to stop thrombolytic therapy. We therefore aimed to systematically review the literature to summarize the available evidence on the predictive value of PFL for hemorrhagic complications after catheter-directed thrombolysis for acute or subacute peripheral native artery or arterial bypass occlusions.
METHODS
A systematic review using a predefined protocol (Appendix, online only) was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 18 The PRISMA checklist is detailed in the Appendix (online only).
Search strategy. We used comprehensive electronic strategies to search PubMed and Embase on January 1, 2016, for studies meeting our predefined eligibility criteria (search query in the Appendix, online only). We cross-checked the reference lists of included articles to identify additional studies until no further studies were found. If multiple publications arose from the same institution reporting (partially) on the same patients, we included only the study with the largest patient sample.
Inclusion criteria. We used the following inclusion criteria for studies: (1) articles published in peerreviewed journals, not restricted to any language; (2) description of original treatment data of adults undergoing continuously administered catheter-directed thrombolysis as primary treatment for acute (<14 days) or subacute (14 days to 3 months) 19 occlusions in at least 80% of the patients; (3) arbitrary number of at least 30 patients treated in the study; (4) data on the treatment of peripheral native artery or arterial bypass occlusions were provided separately from data on the treatment of other types of occlusions, such as venous occlusions; (5) infusion rate of thrombolytic therapy was not changed on the basis of the PFL during treatment; and (6) risk estimates or associations between PFL and hemorrhagic complications were reported or it was possible to estimate the risk or association with the help of the provided data.
Study selection. Two reviewers (M.H.F.P., E.C.B.) independently screened all obtained references by title and abstract for eligibility and independently assessed the full-text papers of potentially eligible articles to determine final inclusion in this systematic review. Disagreement between reviewers was discussed and a final decision was made by consensus (M.H.F.P., E.C.B., G.J.d.B., and C.E.V.B.H.). Two studies could not be evaluated because of the absence of a translator (Japanese, Bulgarian).
Data extraction. We extracted data on study characteristics (year of publication, study design, and number of patients), characteristics of patients (age; sex; smoking; and medical history of hypertension, diabetes mellitus, coronary artery disease, and cerebrovascular disease), characteristics of peripheral occlusions (duration of symptoms, type of occlusion [native artery/ arterial bypass], and length of occlusion), characteristics of thrombolytic therapy (number of thrombolytic infusions performed, agent, dosage, concomitant administration of heparin, reporting of an angiographic protocol, reporting of a protocol for termination of thrombolysis, and duration of infusion), timing of PFL measurement, number of hemorrhagic complications, risk estimates, and associations between PFL and hemorrhagic complications. We used the authors' descriptions of the occurrence of hemorrhagic complications because some studies were published before the Soci Statistical analysis. If studies did not report risk estimates but it was possible to calculate these with the provided data, we estimated the univariable risks with corresponding 95% confidence intervals (CIs). If risk estimates could not be estimated but it was possible to test associations with the provided data, we tested the associations. For continuous values of absolute PFL or relative change in PFL, we used the nonparametric Mann-Whitney U test. For dichotomous data (ie, PFL threshold levels), we used the Fisher exact test. All statistical analyses were performed with IBM SPSS 22 (IBM Corp, Armonk, NY). Associations were considered statistically significant if the P value was < .05.
Risk of bias assessment. Included studies were appraised for risk of bias with the Quality in Prognosis Studies (QUIPS) tool. 21 This tool has been developed for systematic appraisal of studies on prognostic factors and consists of five domains: study participation, prognostic factor measurement, outcome measurement, other possible predictors of outcome, and statistical analysis and reporting. Two reviewers (M.H.F.P. and E.C.B.) independently assessed the risk of bias on the basis of these five domains with predefined criteria.
Outcomes. The primary end points comprised (1) risk estimates (ie, risk ratios or odds ratios) and (2) associations between absolute PFL or (relative) decrease in PFL and hemorrhagic complications at any time during or after treatment.
RESULTS
After screening of 3036 publications, we identified 6 eligible studies (Supplementary Fig; Supplementary  Table I, online only) . 4, 12, [22] [23] [24] [25] Of the included studies, two were randomized clinical trials (RCTs) and four were observational studies. None of the studies provided risk estimates, hampering the evaluation of size and direction of the predictive value of PFL. In one study, two risk estimates were calculated with the published data. 12 Nine associations between PFL and hemorrhagic complications were reported. 4, [22] [23] [24] [25] None of the identified studies was primarily designed to assess the predictive value of PFL for hemorrhagic complications. Three studies used the criteria of the SCVIR/SIR reporting standards 19, 20 for the definition of outcome events, [22] [23] [24] one study used the Thrombolysis in Myocardial Infarction (TIMI) criteria, 12 one study used its own predefined criteria for the outcome events, 25 and one study did not provide the definition of the outcome hemorrhage. 4 Characteristics of included studies. Of the two RCTs included, one compared two thrombolytic agents (either recombinant tissue plasminogen activator [rt-PA] or urokinase [UK]) with surgical revascularization 4 ; the other compared UK with three different doses of recombinant pro-urokinase (r-ProUK). 12 The associations were reported for all thrombolytic treatment arms combined. Of the four cohort studies included, data were prospectively collected in three studies 22, 24, 25 and retrospectively in one study.
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Risk of bias assessment of included studies according to the QUIPS criteria. The rated risk of bias per domain per study can be found in Table I and is exemplified  with quotes and comments in Supplementary Table II  (online only) . None of the studies assessed the predictive value of PFL adjusted for other possible predictors, such as sex, age, comorbidities, thrombolytic regimen, thrombocyte count, use of antiplatelet drugs, and kidney function, leading to a high risk of bias for the domains "other possible predictors of outcome" and "statistical analysis and reporting" in all studies. Moderate and high risk of bias for the first three domains, (ie, study participation, prognostic factor measurement, and outcome measurement) were assigned to studies incompletely describing study population, studies with different timing of PFL measurement between patients, or studies without independent assessment of outcome. Patient characteristics and characteristics of peripheral arterial occlusions. In total, 613 patients underwent 623 thrombolytic procedures for peripheral native artery or arterial bypass occlusions. Study size ranged from 35 to 228 patients. In the two RCTs, 422 patients were described undergoing one thrombolytic procedure per patient. In the four cohorts, 191 patients underwent 201 thrombolytic procedures. The percentage of male patients included varied among studies between 54% and 70%, and the mean age ranged from 57 to 65.4 years. Cardiovascular risk factors of the patients from included studies are summarized in Table II . Characteristics of peripheral arterial occlusions are provided in Table III .
Thrombolytic therapy. A summary of thrombolytic therapy per study can be found in Table III . In two studies, multiple infusions were performed in some patients, 23, 24 but the reasons for these multiple infusions were not specified. Different thrombolytic agents were used in the studies. The following agents were used in the RCTs: one study used either rt-PA (without further specification of type) or UK; and the other study used UK and three different doses of r-ProUK. In the cohorts, the following agents were used: rt-PA (without specification of the type of rt-PA) in one study; reteplase in one study; tenecteplase in one study; and plasmin in one study. The duration of thrombolytic treatment differed between studies from a fixed 5 hours up to a mean of 31 hours. Concomitant heparin was administered during infusion in all studies except one. 23 The timing of PFL measurement varied widely among studies, from only at the beginning and end of treatment to every 6 hours. All but one study reported on the use of an angiographic protocol, 22 and all but three studies reported on the use of a protocol for termination of treatment. 4, 23, 24 Type of PFL measurement and outcomes per study are summarized in Table IV .
Overview of identified studies. The STILE trial compared surgery with thrombolysis. 4 The intention-totreat population for thrombolysis consisted of 249 patients, with a mean age of 65.2 years and 163 (65%) male patients; 194 patients were treated per-protocol. Characteristics of occlusion and thrombolytic therapy were provided only for the intention-to-treat population. The mean duration of symptoms was 49 days for the intention-to-treat population. Two different thrombolytic regimens were used after allocation between surgery and thrombolysis. Patients in the thrombolysis arm were treated with either rt-PA or UK, as chosen by the investigator. The exact definition of major hemorrhage was not provided. The number of patients with major hemorrhage was only provided for the intention-to-treat Two different lytic agents were used, chosen by the investigators, after randomized allocation between surgery and thrombolytic therapy. c Characteristics of occlusions and thrombolytic therapy presented here are from the intention-to-treat population because these were not provided for the per-protocol population. population. The exact number of patients with major hemorrhage in the per-protocol population for whom the association between PFL and major hemorrhage is provided is unknown. PFL was measured at the end of infusion. Median PFL was 188 mg/dL with major hemorrhage and 310 mg/dL without major hemorrhage, resulting in a significant association (P ¼ .01) with more major hemorrhagic complications in patients with lower PFL at the end of infusion. No risk estimate was provided or could be estimated.
The Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy (PURPOSE) trial is a four-arm RCT. Two hundred twenty-eight patients were included, of which 73 patients had an occlusion of a peripheral native artery and 155 patients had an occlusion of an arterial bypass. 12 The mean age was 65 years, and 143 (63%) patients were male. The mean duration of symptoms was 4.5 days. In this study, UK was compared with three different doses of r-ProUK; 60 patients were treated with UK, 61 patients with r-ProUK 2 mg/h, 55 patients with r-ProUK 4 mg/h, and 52 patients with r-ProUK 8 mg/h. Major bleeding was defined as "any hemorrhagic event terminating in death, intracranial hemorrhage, or a drop in hemoglobin of 5 g/dL or hematocrit of 15 percentage points, whether or not there was observed blood loss." 12 PFL was measured in 195 patients, and of these, 35 developed a major bleeding and 118 patients had any bleeding. Two risk estimates could be calculated with the presented data; a relative risk of 0.33 (95% CI, 0.05-2.25) for major bleeding was found in patients with PFL of <100 mg/dL vs $100 mg/ dL, and a relative risk of 1.39 (95% CI, 1.06-1.81) for any bleeding was found in patients with PFL of <100 mg/dL vs $100 mg/dL. PFL measurements were performed after 8 hours and at the end of treatment. In a prospective cohort study, 35 patients were included, of which 14 patients had an occlusion of a peripheral native artery and 21 patients had an occluded bypass. 22 The mean age was 57 years, and of the included patients, 19 (54%) were male. The duration of symptoms was <14 days in all patients. All patients were treated with rt-PA with a mean dose of 1.7 mg/h. The mean duration of infusion was 19.5 hours. Adverse events happened in eight patients and were defined as either a major or a minor hemorrhagic complication, according to the criteria of the SCVIR guidelines of 2001. 20 PFL measurements were available in 33 of 35 patients. Three associations were estimated between (1) PFL nadir and adverse events, (2) absolute decrease in PFL compared with baseline and adverse events, and (3) percentage change in PFL compared with baseline and adverse events. All three associations were reported as not significant, with P > .05. No risk estimates were provided or could be calculated. In a retrospective cohort study, 36 patients were included undergoing 40 thrombolytic infusions, of which 16 infusions were performed for peripheral native artery occlusions and 24 infusions were performed for an occluded arterial bypass. 23 Baseline characteristics were provided only per infusion, not per patient, and therefore we are not able to report on the baseline characteristics on a patient level. The inclusion of patients was restricted to a duration of symptoms <7 days. All patients were treated with reteplase, combined with abciximab in 21 patients and without abciximab in 19 patients. The mean duration of thrombolysis was 31 hours. The timing of PFL was not reported. Major complications occurred during nine thrombolytic infusions and were defined as "procedure-related events within 30 days of the procedure including death, cerebral hemorrhage, myocardial infarction, bleeding requiring transfusion of 2 units of packed red blood cells, or significant clinical event causing an increased level of care or premature abandonment of thrombolysis" according to the criteria of the SIR guidelines of 2003. 19 All presented associations were statistically significant; namely, the association between (1) PFL <100 mg/dL vs PFL >100 mg/dL and major hemorrhagic complications (P ¼ .024), (2) a lower nadir PFL and major hemorrhagic complications (P < .001), and (3) percentage change in PFL and major hemorrhagic complications (P < .001). No risk estimates were provided or could be calculated because all results were presented per infusion and not per patient.
In a prospective cohort study, 37 patients were included undergoing 43 thrombolytic infusions, of which 16 infusions were performed for peripheral native artery occlusions and 27 infusions were performed for an occluded arterial bypass. 24 Baseline characteristics were provided only per infusion, not per patient. Inclusion of patients was restricted to a duration of symptoms <14 days. All patients were treated with tenecteplase with a dose of 0.25 mg/h in 22 patients and 0.125 mg/h in 21 patients, with a mean duration of infusion of 24 hours. The association was estimated between percentage change in PFL (after thrombolysis compared with before thrombolysis) Total number of thrombolytic infusions was 228. c We estimated these risk ratios and 95% CIs based on the published data. The number of patients with adverse events is provided only for all patients and not seperately for the patients with PFL measurement. and major bleeding, defined according to the criteria of the SIR guidelines of 2003. 19 PFL was measured during all 43 thrombolytic procedures, during which 3 major bleeding events occurred. The P value was not quantified, but only the nonsignificance of the association was stated. No risk estimate was provided or could be calculated.
In a prospective cohort study, 83 patients were included, of which 34 patients had a peripheral native artery occlusion and 49 patients had an occluded arterial bypass. 25 The mean age was 64.3 years, and the majority of the patients were male (70% 
DISCUSSION
In our systematic review, two risk estimates and nine associations between PFL and hemorrhagic complications were found. Heterogeneity in time point of measurement of PFL, use of different thrombolytic agents and different dosages between and within studies, relatively small sample sizes, and differences in definition of outcomes did not allow us to draw a conclusion on the predictive value of PFL measurement for hemorrhagic complications. PFL seems inaccurate in predicting hemorrhagic complications. In the present study, we did not identify any study that was primarily designed to assess the predictive value of PFL for hemorrhagic complications after catheter-directed thrombolysis.
Every thrombolytic treatment confers a risk of hemorrhagic complications because of an induced fibrinolytic or anticoagulated state and a loss of vessel integrity at the puncture site. A variety of thrombolytic agents were used in the included studies. These agents do not degrade fibrinogen directly but activate the conversion of plasminogen to plasmin. 26 Plasmin in turn degrades fibrinogen and fibrin into fibrinogen degradation products. UK is characterized by so-called non-fibrin-specific plasminogen activation. 26 Recombinant tissue-type plasminogen activators (rt-PA) are characterized by more fibrin-bound plasminogen activation and affinity for plasminogen with the theoretical advantage of a lower rate of hemorrhagic complications. However, data from trials using different thrombolytic agents showed no statistically significant difference in hemorrhagic complications between UK and rt-PA. 27 Two recent studies investigating intravenous thrombolysis with rt-PA as treatment for ischemic stroke found a significant association of change in PFL after treatment compared with baseline and intracranial hemorrhage. 28, 29 These findings are different from our results, but this difference could be explained by the intravenous mode of administration of the thrombolytic agent and the different localization of the occlusions in stroke patients. No recent studies report on an association between PFL and hemorrhagic complications in thrombolysis for myocardial infarction. However, in the Thrombolysis in Myocardial Infarction (TIMI) II trial, in which rt-PA was intravenously infused, no association between PFL <100 mg/dL and major hemorrhagic complications was found, whereas PFL <100 mg/dL was associated with the occurrence of minor and major hemorrhagic complications combined. 30 This finding was similar to the RCT on catheter-directed thrombolysis with UK or r-ProUK for peripheral native artery and arterial bypass occlusions from which we calculated two risk estimates. In that study, a PFL of <100 mg/dL led to a significantly higher risk of any bleeding but no higher risk of major bleeding.
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The main strength of our systematic review is the extensive and comprehensive literature search with which we provide the first summary of all available data on the predictive value of PFL for hemorrhagic complications after catheter-directed thrombolytic therapy for peripheral native artery and arterial bypass occlusions. This systematic review, however, has several limitations. The included series were small and mostly individually underpowered to determine the predictive value of PFL for hemorrhagic complications, even though we restricted inclusion of studies to those with a sample size larger than 30 patients to decrease the chance of type II errors. Moreover, risk estimates could be calculated in only one study, and none of the studies assessed the predictive value of PFL for hemorrhagic complications adjusted for other possible predictors, such as sex, age, comorbidities, thrombolytic regimen, thrombocyte count, use of antiplatelet drugs, and kidney function. Eighty studies on catheter-directed thrombolysis for peripheral native artery or arterial bypass occlusions reporting PFL were excluded because no association between PFL and hemorrhagic complications was provided or could be calculated (Supplementary Table I , online only). This might lead to an overestimation of the effect because significant associations are more likely to be published. Finally, comparability of the included studies is hampered by the use of different thrombolytic agents and doses, differences in duration of symptoms, type of occlusion, moment of PFL measurement, and definition of outcomes. For this reason, published reporting standards should be applied. 15 The most recent Cardiovascular and Interventional Radiological Society of Europe and SIR (former SCVIR) quality improvement guidelines of 2013 defined major hemorrhage as the composite of intracranial hemorrhage of any size and hemorrhages that result in death and a "hemorrhage of sufficient magnitude that it leads to (i) extended or unexpected hospitalization, (ii) surgery to arrest the hemorrhage, or (iii) the need for blood transfusion of two or more units." 15 To improve the comparability between studies, we would encourage future studies to report the number of each event per patient separately and grouped as major hemorrhage, according to the classification of complications in the reporting standards. Our findings have implications for future clinical guidelines and future research because the role of PFL for monitoring thrombolysis and predicting hemorrhagic complications remains unclear; at present, no definitive conclusions can be drawn from the available studies. In future research, adjustment for other predictors that influence the risk of hemorrhage, hemorrhagic stroke, and mortality after intra-arterial thrombolysis should be applied in assessing the predictive value of PFL. Furthermore, apart from identification of prognostic factors, developing a prediction model for hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions will help patients and clinicians weighing the individualized risk for hemorrhagic complications after thrombolytic therapy against the probability of success of thrombolytic therapy.
CONCLUSIONS
A limited number of heterogeneous studies reported unadjusted risk estimates and associations between PFL and hemorrhagic complications after catheterdirected thrombolysis for acute or subacute peripheral native artery or arterial bypass occlusions. There were considerable differences in the time point of PFL measurement, the thrombolytic agents, the dosages of the agents, and the definition of the outcomes. As a result, the clinical role of PFL in predicting hemorrhagic complications after catheter-directed thrombolysis for acute or subacute peripheral native artery or arterial bypass occlusions is unproven. Because the current literature neither supports nor opposes the role of PFL to monitor catheter-directed thrombolysis and to predict hemorrhagic complications after thrombolysis, studies assessing the predictive value of PFL for hemorrhagic complications after catheter-directed thrombolysis are warranted. Moreover, clinical prediction rules, using multiple predictors, to assist treatment decisions during catheter-directed thrombolysis are awaited. 
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APPENDIX (online only).
Protocol for a systematic review on plasma fibrinogen level as a possible predictor of hemorrhagic complications during thrombolysis for acute or subacute peripheral arterial occlusions Background. Acute or subacute limb ischemia is a severe condition and requires urgent medical evaluation and management. Treatment aims are revascularization and decreasing the risk of limb loss, but treatment also confers a risk of hemorrhagic complications varying from 6.2% to 8.4% for major hemorrhage and 21.9% to 43.8% for minor hemorrhage. 1 The clinical use of plasma fibrinogen level (PFL) to predict hemorrhagic complications is controversial. It is thought that a low PFL is significantly correlated with an increased risk of hemorrhagic complications, but the prediction is not accurate.
Purpose. The aim of this systematic review of the literature is to summarize the available evidence on the predictive value of PFL and hemorrhagic complications in patients undergoing thrombolysis for acute or subacute peripheral arterial occlusions and bypass occlusions.
Methods/design. We will follow the recommendations made by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
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Data sources. We will conduct an electronic search using PubMed and Embase on January 1, 2016. Reference lists of identified articles will be cross-checked to identify additional studies until this method of crosschecking does not identify further studies.
Search strategy. We developed a systematic search strategy with structured terms (see later).
Eligibility criteria. Studies will be included if they fulfill the following criteria: (1) articles published in peerreviewed journals without language restrictions; (2) description of original treatment data of adults undergoing continuously administered catheter-directed thrombolysis as primary treatment for $80% acute (defined as #14 days) or subacute (defined as 14 days to 3 months) occlusions; (3) we will use an arbitrary cutoff of >30 patients per study; (4) data on peripheral native arterial or peripheral arterial bypass occlusions provided separately from data on other (eg, venous) occlusions; (5) infusion rate of thrombolytic treatment was not changed on the basis of PFL measured during thrombolysis; and (6) risk estimates or associations between PFL and hemorrhagic complications were reported or it was possible to estimate the risk or association on the basis of the published data.
Study selection. Two authors (M.H.F.P. and E.C.B.) will independently screen all obtained references by title and abstract for eligibility for inclusion. Studies that do not meet the criteria according to the titles or abstracts will be excluded. Full-text versions of the remaining studies, including those that are potentially eligible studies and uncertain, will be retrieved for a second review by two reviewers (M.H.F.P. and E.C.B.) independently to determine final inclusion in this review.
Data extraction. We will develop a data extraction form. The data items mainly extracted are as follows:
Study characteristics: year of publication, study design, and number of patients. Patient characteristics: age; sex; smoking; and medical history of hypertension, diabetes, coronary artery disease, and cerebrovascular disease. Characteristics of peripheral occlusions: duration of symptoms, type of occlusion (native artery/bypass) and length of occlusion. Thrombolytic therapy: number of thrombolytic infusions performed, agent, dose, concomitant heparin therapy, angiographic protocol, protocol for termination of thrombolysis, and duration of infusion. Number of events per outcome, description of PFL, and association between fibrinogen and outcome: number of hemorrhagic complications, timing of PFL measurement (nadir, absolute decrease, relative decrease compared with baseline), risk estimates or associations between PFL and hemorrhagic complications.
Outcome. The outcome measures for this review are preferably risk estimates (ie, risk ratios or odds ratios) or, if no risk estimates are provided, associations between PFL and hemorrhagic complications at any time during treatment.
Statistical analysis. If studies do not report risk estimates but these could be calculated with the provided data, we will estimate the univariable risks including 95% confidence intervals ourselves. If risk estimates could not be estimated but associations could be tested with the provided data, we will test these ourselves. For continuous values of PFL or change in PFL, we will use the nonparametric Mann-Whitney U test. For dichotomous data (ie, PFL threshold levels), we will use the Fisher exact test. All statistical analyses will be performed with IBM SPSS 22 (IBM Corp, Armonk, New York). Associations will be considered statistically significant if the P value is < .05. Supplementary Fig (online only) . Flow chart detailing the number of studies excluded and included at each step of the literature search (updated January 1, 2016 
Results
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, illustrated with a flow diagram.
and Supplementary Fig
Study characteristics 18 For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations. Tables II, III , and IV
Risk of bias within studies 19
Present data on risk of bias of each study and, if available, any outcome level assessment. Table I and  Supplementary  Table II Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, healthcare providers, users, and policy makers).
7-8 Limitations 25
Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete retrieval of identified research, reporting bias).
7-8
Conclusions 26
Provide a general interpretation of the results in the context of other evidence, and implications for future research. 69 Graor, 1985 70 Graor, 1986 71 Graor, 1986 72 Graor, 1988 73 Graor, 1990 74 Gurll, 1976 75 Hallett, 1983 76 Han, 2010 77 Hargrove, 1982 78 Hargrove, 1982 79 Hess, 1982 80 Hess, 1987 81 Hess, 1996 82 Holden, 1990 Table II , comprising three r-ProUK groups (2 mg, 4 mg, or 8 mg/h for 8 hours, followed by 0.5 mg/h in each group) and one urokinase group (4,000 IU/min for 4 hours, followed by 2,000 IU/min). After gaining access into the thrombus, a 2,000 U heparin bolus was to be administered, followed by a continuous infusion of 500 U/h, of which not more than 100 U/h was to be administered through the arterial sheath." (p. 1084-1085) 
